No spam. Unsubscribe anytime.
HPLC Purity Analysis
Retatrutide
CAS: 2381089-83-2
energy-balance research with extreme metabolic research potential (>24% in trials) · glucose-regulation research management · Triple incretin receptor pharmacology
Retatrutide is a triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon (GCGR) receptors.
- energy-balance research with extreme metabolic research potential (>24% in trials)
- glucose-regulation research management
- Triple incretin receptor pharmacology
- Hepatic fat reduction and NASH
This product is intended for laboratory research purposes only. Not for human consumption. Handle with appropriate safety precautions.
Frequently Bought Together
Bacteriostatic Water
Required for reconstitution
Semaglutide
GLP-1 / Weight Management
No spam. Unsubscribe anytime.
HPLC Purity Analysis
Specifications
How Retatrutide Works
Retatrutide is a triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon (GCGR) receptors. GLP-1 and GIP agonism drive insulin secretion and appetite suppression, while glucagon receptor activation increases energy expenditure and hepatic lipid oxidation. This triple mechanism addresses multiple metabolic pathways for potentially superior metabolic research and metabolic improvement over dual agonists.
Research Applications
Pricing
| Size | Per Vial | 10-Pack | Savings |
|---|---|---|---|
5mg | $149.95 | $1499.50 | — |
10mgSale | $95.95$249.95 | $959.50 | 62% off |
15mg | $349.95 | $3499.50 | — |
20mgSale | $139.95$639.95 | $1399.50 | 78% off |
30mgSale | $190.95$300.00 | $1909.50 | 36% off |
60mgBest Value | $400.00 | $4000.00 | — |
10-pack pricing shown. Volume discounts for 50+ vials — contact us.
Certificate of Analysis
This COA is a representative sample. A batch-specific Certificate of Analysis with full HPLC chromatograms and mass spectrometry data is included with every order.
Research Use Only. This product is intended for laboratory research purposes only. Not for human consumption. Handle with appropriate safety precautions.
Related Peptides
Up to 50% OffSemaglutide
Clinically studied for steady weight reduction — once weekly
Up to 60% OffTirzepatide
The most studied dual-agonist for weight reduction
Up to 38% OffLiraglutide
Daily GLP-1 studied for steady appetite regulation
Up to 13% OffCagrilintide
Studied for amylin-mediated satiety pathways beyond GLP-1